Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences

被引:222
作者
Viles-Gonzalez, JF [1 ]
Fuster, V [1 ]
Badimon, JJ [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Cardiovasc Biol Res Lab, New York, NY 10029 USA
关键词
atherothrombosis; atherosclerosis; tissue factor; antithrombotic therapy; antiplatelet therapy; noninvasive imaging;
D O I
10.1016/j.ehj.2004.03.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherothrombosis, characterised by atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes (ACS) and cardiovascular death. It is the leading cause of mortality in the industrialised world. Atherosclerosis is a diffuse process that starts early in childhood and progresses asymptomaticalty through adult life. Later in life, it is clinically manifested as coronary artery disease, stroke, transient ischaemic attack, and peripheral arterial disease. From the clinical point of view, we should envision this disease as a single pathologic entity that affects different vascular territories. Available antithrombotic therapy is very safe and efficient but the morbidity and mortality due to atherothrombosis is still unacceptably high. Recent evidence suggests that inhibition of tissue factor or elements in the tissue factor pathway (i.e., factors VIIa and Xa, or thrombin) has the potential to further improve outcomes in atherothrombosis. Here, we will review the most important concepts and advances in the pathogenesis, prevention, and antithrombotic treatment of this widespread disease. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1197 / 1207
页数:11
相关论文
共 110 条
[31]  
Dimmeler S, 1997, CIRCULATION, V95, P1760
[32]   First experience with direct factor Xa inhibition in patients with stable coronary disease - A pharmacokinetic and pharmacodynamic evaluation [J].
Dyke, CK ;
Becker, RC ;
Kleiman, NS ;
Hochman, JS ;
Bovill, EG ;
Lincoff, AM ;
Gerstenblith, G ;
Dzavik, V ;
Gardner, LH ;
Hasselblad, V ;
Zillman, LA ;
Shimoto, Y ;
Robertson, TL ;
Kunitada, S ;
Armstrong, PW ;
Harrington, RA .
CIRCULATION, 2002, 105 (20) :2385-2391
[33]   Fibrinogen: a predictor of stroke and marker of atherosclerosis [J].
Eidelman, RS ;
Hennekens, CH .
EUROPEAN HEART JOURNAL, 2003, 24 (06) :501-502
[34]   Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement:: the METHRO II randomised trial [J].
Eriksson, B ;
Bergqvist, D ;
Kälebo, P ;
Dahl, OE ;
Lindbratt, S ;
Bylock, A ;
Frison, L ;
Eriksson, UG ;
Welin, L ;
Gustafsson, D .
LANCET, 2002, 360 (9344) :1441-1447
[35]  
Eriksson BI, 2002, THROMB HAEMOSTASIS, V87, P231
[36]   In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta - A comparison with transesophageal echocardiography [J].
Fayad, ZA ;
Nahar, T ;
Fallon, JT ;
Goldman, M ;
Aguinaldo, JG ;
Badimon, JJ ;
Shinnar, M ;
Chesebro, JH ;
Fuster, V .
CIRCULATION, 2000, 101 (21) :2503-2509
[37]  
Fayad ZA, 2000, CIRCULATION, V102, P506
[38]   Prospective study of markers of hemostatic function with risk of ischemic stroke [J].
Folsom, AR ;
Rosamond, WD ;
Shahar, E ;
Cooper, LS ;
Aleksic, N ;
Nieto, FJ ;
Rasmussen, ML ;
Wu, KK .
CIRCULATION, 1999, 100 (07) :736-742
[39]   Epidemic of cardiovascular disease and stroke: The three main challenges - Presented at the 71st Scientific Sessions of the American Heart Association - Dallas, Texas [J].
Fuster, V .
CIRCULATION, 1999, 99 (09) :1132-1137
[40]  
FUSTER V, 1992, NEW ENGL J MED, V326, P310